ArticleMedicine2026
Peripheral blood markers predict prognosis in patients with advanced non-small cell lung cancer receiving immunotherapy.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, immunotherapy has significantly reshaped the pattern of non-small cell lung cancer (NSCLC) treatment. However, the issue of how to pinpoint potential responsive populations more accurately warrants immediate and focused attention. This study mainly explored the correlation between baseline peripheral blood biomarkers and prognosis in patients with advanced NSCLC undergoing immunotherapy. A retrospective analysis was performed on 139 patients diagnosed with advanced NSCLC who underwent first-line immunotherapy treatment between 2019 and 2022. Baseline demographic information and peripheral blood parameter data were collected. The Cox proportional hazards regression model was used to estimate hazard ratios and 95% confidence intervals to identify independent prognostic factors, while Kaplan-Meier survival analysis with log-rank tests was applied to compare survival differences between groups. Finally, the predictive efficacy of biomarkers was assessed utilizing the receiver operating characteristic curve. C-reactive protein (CRP) and carcinoembryonic antigen (CEA) were independent predictors for both progression-free survival (PFS) and overall survival (OS). Eosinophils > 0.23 × 109/L, PLT (platelets) > 228 × 109/L, albumin ≤ 37.2g/L, CRP > 6.21mg/L, or CEA > 6.23ng/ml was associated with poorer PFS. Meanwhile, (hemoglobin) ≤ 132g/L, platelets > 228 × 109/L, CRP > 7.59mg/L, or CEA > 7.39ng/ml may imply an inferior OS outcome. And the combination of CRP and CEA yielded areas under the curve with 0.675 and 0.656 for predicting PFS and OS, respectively. CRP and CEA hold the potential to predict the prognosis of advanced NSCLC patients undergoing first-line immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.